Roche and Biogen Idec’s cancer drug Rituxan has been found to extend the lives of follicular lymphoma patients, according to a late-stage study.
The disease is a common, incurable but slow-developing form of non-Hodgkin’s lymphoma (NHL) and accounts for about one in four of all cases.
The study was stopped early after Rituxan, known as MabThera outside the US, met its target of extending the time patients live with their disease under control during a pre-planned interim analysis. Rituxan is co-marketed by Genentech.
Copyright Press Association 2009